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ABSTRACT
Background: Herpes simplex virus type 2 (HSV-2)
infection increases acquisition and transmission of HIV,
but the results of trials measuring the impact of HSV-2
therapy on HIV genital shedding and HIV acquisition are
mixed, and the potential impact of HSV-2 therapy on the
incidence of HIV at the population level is unknown.
Methods: The effects of episodic and suppressive HSV-2
therapy were simulated using the individual-level model
STDSIM fitted to data from Cotonou, Benin (relatively low
HIV prevalence) and Kisumu, Kenya (high HIV prevalence).
Clinician- and patient-initiated episodic therapy, started
when symptomatic, were assumed to reduce ulcer
duration. Suppressive therapy, given regardless of
symptoms, was also assumed to reduce ulcer frequency
and HSV-2 infectiousness.
Results: Clinician-initiated episodic therapy in the general
population had almost no effect on the incidence of HIV.
The impact of patient-initiated therapy was higher
because of earlier treatment initiation, but still low (,5%)
unless symptom recognition and treatment-seeking
behaviour were very high. Suppressive therapy given to
female sex workers (FSW) in Kisumu had little effect on
population HIV incidence. In Cotonou, suppressive therapy
in FSW with high coverage and long duration reduced
population HIV incidence by .20% in the long term.
Impact was increased in both cities by also treating a
proportion of their clients. Long-term suppressive therapy
with high coverage in the general population could reduce
HIV incidence by more than 30%.
Conclusions: These results show that HSV-2 therapy
could potentially have a population-level impact on the
incidence of HIV, especially in more concentrated
epidemics. However, a substantial impact requires high
coverage and long duration therapy, or very high symptom
recognition and treatment-seeking behaviour.
HIV and herpes simplex virus type 2 (HSV-2) have
a synergistic relationship. HIV affects HSV-2
shedding, ulcer recurrence rate and ulcer dura-
tion.
1–5 HSV-2, in turn, has a strong impact on HIV
transmission and acquisition and probably also
affects the natural history of HIV infection.
2 4 6–14 A
meta-analysis of longitudinal studies found HSV-2
seropositivity to be associated with a risk ratio of
HIV acquisition of 2.7 (95% confidence interval
(CI) 1.9 to 3.9) in men and 3.1(95% CI 1.7 to 5.6) in
women,
15 and most cross-sectional studies have
found a correlation between HSV-2 and HIV viral
shedding and/or quantity.
10 16 17
Antiviral therapy against HSV-2 could thus have
a population-level impact on the global HIV
epidemic in areas with a high HSV-2 prevalence
such as sub-Saharan Africa.
41 51 8 Two types of
therapy exist: episodic and suppressive.
Episodic therapy is given to individuals with
HSV-2 ulcers who notice their symptoms.
Clinician-initiated therapy requires the patient to
seek treatment for each ulcer episode, while
patient-initiated therapy requires patients to self-
medicate, reducing treatment delays. Three trials
have assessed the effect of clinician-initiated
episodic HSV-2 therapy on HIV infectiousness
and results are currently available for two of these.
A trial in women in Ghana and the Central African
Republic found no significant impact on genital
HIV RNA or time to ulcer healing.
19 A trial in men
in South Africa found a significant reduction in
ulcer healing times and a borderline significant
reduction in detection and quantity of ulcer HIV-1
shedding at day 7.
20
Suppressive therapy is given to HSV-2 positive
individuals regardless of whether they have symp-
toms. Six published trials have assessed the effect
of HSV-2 suppressive therapy on genital HIV viral
load in HIV/HSV-2-infected individuals who had
not received antiretroviral therapy.
21–26 Five found a
significant reduction in frequency of genital shed-
ding of HIV RNA and four found a significant
reduction in the quantity of genital shedding of
HIV RNA. All four studies that used valacyclovir or
800 mg twice daily acyclovir found a significant
impact on frequency and quantity,
21 23 24 26 whereas
only one of those using acyclovir 400 mg twice
daily found an impact on frequency and neither
had an impact on quantity.
22 25 The half-life of
valacyclovir is about double that of acyclovir.
27
Two trials have assessed the effect of acyclovir
400 mg twice daily on HIV acquisition.
28 29 No
impact was observed in either trial,
28 29 suggesting
that this dose may be too low for HIV prevention.
The results of a randomised trial of suppressive
therapy with acyclovir 400 mg twice daily on HIV
transmission among discordant couples are
expected in 2009.
Mathematical modelling can be used to explore
the potential population-level impact of data from
individual-level trials. Very few modelling studies
have examined the relationship between HSV-2
and HIV,
30–33 and none have examined the impact
of HSV-2 antiviral therapy on the incidence of HIV
in sub-Saharan Africa where such interventions are
likely to prove most useful.
The aim of this paper is to explore the potential
population-level impact of episodic and suppressive
HSV-2 therapy on the incidence of HIV in one low
and one high HIV prevalence city in sub-Saharan
Africa.
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Data, model and baseline model scenarios
The mathematical model STDSIM has been fitted to data
collected from four cities in sub-Saharan Africa as detailed in our
previous publications.
33 34 The model was fitted to data from the
Study Group on Heterogeneity of HIV epidemics in African
Cities
35 for the year 1997 and to available data on trends over
time.
STDSIM is an individual-level stochastic model that simulates
the natural history and interactions between HIV, HSV-2,
syphilis, gonorrhoea, chlamydia and chancroid. It has been
described in detail elsewhere.
32 36–39 STDSIM is able to simulate
realistic sexual networks and heterogeneity between individuals
in sexual behaviour and in the natural history of infection. It
has also previously been used to explore the impact of treatment
for sexually transmitted infections and male circumcision on
HIV-1 prevention and the heterogeneous spread of HIV-1 in
Africa, and the diverging HIV-1 and HIV-2 prevalence trends in
West Africa.
33 34 40 45
The model representation of the natural history of sexually
transmitted infections and, importantly, the interaction
between HIV and other sexually transmitted infections were
parameterised based on the literature where possible and poorly
known parameter values have been subject to sensitivity
analysis.
33 34 Full details are shown in Section S1 of the online
supplement.
In this paper we present results for the two cities in the study
with the lowest (Cotonou, Benin) and highest (Kisumu, Kenya)
HIV prevalence. Cotonou represents an HIV epidemic highly
concentrated among female sex workers (FSW) and their clients,
while Kisumu represents a more generalised HIV epidemic
typical of Eastern and Southern Africa.
34
Simulated interventions
For episodic and suppressive therapy we proposed a low,
medium and high value for each of the required model
parameters. The medium values were combined in one scenario
to give the most likely estimate of impact and the low and high
parameter values were combined in two further scenarios to
give a plausible range for the impact of the intervention.
Episodic therapy
Clinician-initiated episodic therapy for HSV-2 was targeted at a
proportion of symptomatic individuals who were simulated to
recognise their ulcer, seek treatment and benefit from reduced
ulcer duration. Full details are shown in Section S2 of the online
supplement.
Patient-initiated episodic therapy for recurrent HSV-2 ulcers
was targeted at a proportion of symptomatic individuals who
were simulated to recognise their symptoms, self-treat and
benefit from reduced ulcer duration. In this scenario we
simulated clinician-initiated episodic therapy for primary ulcers
(full details in Section S2 of the online supplement). For
recurrent ulcers we assumed the same proportion recognised
their symptoms as for clinic-based therapy, but assumed a
higher proportion of those with recurrent ulcers received
treatment because of the less frequent need for clinic visits,
and assumed a greater reduction in ulcer duration because of the
earlier initiation of treatment. Full details are shown in Section
S3 of the online supplement.
For both clinician- and patient-initiated episodic therapy, the
target group was the general population and the simulated
intervention was ongoing from 1 January 2008.
Suppressive therapy
Suppressive HSV-2 therapy was initiated in a proportion of
HSV-2 infected individuals who were simulated to start therapy
and stop after a finite period of time. Suppressive therapy was
assumed to increase the interval between ulcers, reduce the
duration of ulcers and reduce the infectiousness of HSV-2 (but
had no direct effect on HIV). We proposed a low, medium and
high value for each of these parameters. Full details are shown in
Section S4 of the online supplement.
Suppressive therapy was targeted at a proportion of the
simulated population in a risk group. Individuals within this
target group who were HSV-2 infected on 1 January 2008 and
individuals who became HSV-2 infected after this date were
simulated to receive suppressive therapy for 2 years, 10 years or
until death. We assumed that, once individuals stopped
suppressive treatment, they did not restart. The simulated
target groups and coverage were: (1) 25%, 50%, and 75% of
FSW; (2) 50% of FSW and 10%, 30% and 50% of male clients;
(3) 10%, 30% and 50% of the general population.
Outcome for episodic and suppressive therapy
We calculated the percentage reduction in the mean annual
HSV-2 and HIV incidence among subjects aged 15–49 years in
the general population over 5 and 20 years in the intervention
scenarios compared with the baseline scenarios.
Sensitivity analysis
We assessed the robustness of our findings to key baseline and
intervention parameter values known to affect impact. Full
details are shown in Section S5 of the online supplement.
RESULTS
Baseline scenario
A good fit of the model simulations to data for demography,
sexual behaviour and epidemiology of the two populations was
achieved and has been presented elsewhere.
33 34
The fit of model-simulated HSV-2 prevalence to data from
the two cities is shown in fig 1. The prevalence of HSV-2 in
younger age groups was fitted preferentially because younger
individuals account for a higher proportion of new HIV and
HSV-2 infections. As a result, the prevalence of HSV-2 was
underestimated in older women in Cotonou. In both sites the
prevalence of HSV-2 in younger men was allowed to be
overestimated in favour of fitting the prevalence of HSV-2 in
younger women because higher-risk men may not have been
completely captured in the original surveys.
46 The fit of HSV-2
prevalence reflects the general age trends in HSV-2 prevalence
and the important differences between the two sites, such as
the difference in HSV-2 prevalence in women aged 15–19 years
in Cotonou (9%) and Kisumu (39%).
47 Owing to the sensitivity
of the simulated prevalence of HIV and the prevalence of short-
duration sexually transmitted infections to the change in sexual
behaviour parameters, these parameters could not be further
altered to improve the fit for HSV-2 without worsening the fit
for HIV and the other sexually transmitted infections.
The model provided a reasonable fit to the age and sex
patterns in HIV in both sites (fig 1). The model replicated the
observed patterns, including the much higher prevalence of HIV
among young women compared with young men. In Cotonou
the prevalence of HIV was very similar among men and women,
as observed. In Kisumu the prevalence of HIV peaked at a
younger age in women than in men. The model fits the
observed prevalence of HIV in the general population in 1997
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reasonably well.
Interventions
The effects of the interventions in terms of percentage
reduction in HSV-2 and HIV incidence over 5 and 20 years in
the two cities are shown in figs 2 and 3. The point estimates
result from simulations assuming medium scenario options for
all parameters, and the plausible bound from assuming all high
or all low values. For simplicity, it is assumed that there are no
other changes in interventions and no antiretroviral therapy
over the period.
Episodic therapy
With the medium scenario options, clinician-initiated episodic
therapy had almost no effect on the incidence of HSV-2 or HIV
in the short or long term in either city (right-hand side of graphs
in figs 2 and 3). Patient-initiated therapy was only slightly more
effective.
The upper plausible bound for episodic therapy, which
assumes that the highest value of each parameter is correct,
suggests that reductions in incidence are possible, especially
with patient-initiated therapy. The sensitivity analysis of the
effect of changing each parameter individually is shown in fig S1
in the online supplement. The increase in the proportion who
recognise their symptoms had the largest effect on the impact
on both HSV-2 and HIV incidence. Assuming 60% of
individuals recognised their ulcers (and medium options for
the other parameters), over 20 years clinician-initiated therapy
reduced the incidence of HIV by 5.0% in Cotonou and 2.9% in
Kisumu and patient-initiated therapy reduced the incidence of
HIV by 15.1% and 9.8%, respectively.
Suppressive therapy
Suppressive therapy in FSW in Kisumu had only a marginal
effect on the incidence of HSV-2 and HIV, even with high
coverage long-term therapy (figs 2 and 3). Treating half the FSW
and a smaller proportion of their clients was more effective,
leading to reductions in the incidence of HSV-2 of up to 30%
and in the incidence of HIV of more than 10% in the long term.
In Cotonou, even giving long-duration suppressive therapy to
FSW alone resulted in reductions of .30% in HSV-2 and .20%
in HIV over the long term, and these were further increased by
treating clients. Short-duration therapy (2 years) produced only
small reductions in incidence in both cities.
Figure 1 Observed (95% CI) and
simulated prevalence of HIV and herpes
simplex virus 2 (HSV-2) by age and sex in
1997 and over time in Cotonou and
Kisumu (15–49 years). Note the
difference in the y-axis scale used on HIV
prevalence graphs. Gen pop, general
population. ANC, antenatal clinic; F,
female; M, male.
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can produce greater reductions in incidence over 20 years, with
the effect rising steeply with the proportion of the population
treated in both cities. With 30–50% of the population treated
for 10 years, reductions in the incidence of HIV of 20–30% over
20 years were predicted (fig 3).
The sensitivity analysis of the effect of changing each
intervention parameter value individually (see fig S2 in the
online supplement) shows that the effect on HSV-2 infectivity
has the largest effect on HSV-2 incidence, and that effects on
ulcer duration are more important for HIV incidence. However,
the results were fairly insensitive to altering any one parameter
alone.
Sensitivity analysis of baseline parameter values
Figure S3 in the online supplement shows the sensitivity of the
results for episodic and suppressive therapy to the assumptions
made about co-factor effects in different stages of HSV-2
infection. As expected, these changes had no impact on the
incidence of HSV-2 incidence.
Assuming a between-ulcer co-factor effect, while keeping the
population attributable fraction of HSV-2 on HIV transmission
constant by reducing the co-factor effects during ulceration,
reduced the impact of both episodic and suppressive therapy on
the incidence of HIV in both cities. This is because therapy acts
on the ulcer stages, so if they contribute less to the total co-
factor effect, the potential benefit of therapy would be reduced.
Changing HSV-2 ulcer co-factors had larger impacts on the
effects of treatment on the incidence of HIV, affecting both
episodic and, particularly, suppressive therapy. However, co-
factor effects of this magnitude do not fit well with the
observed relative risks for the association of HSV-2 and HIV.
DISCUSSION
This modelling study shows that effective treatment of HSV-2
could theoretically reduce the incidence of HIV sufficiently for a
substantial public health impact. However, the impact depends
on high coverage and long duration of therapy, or very high
symptom recognition and treatment-seeking behaviour.
Episodic therapy would be easier to introduce and sustain
than suppressive therapy as patients would already have
presented for treatment and should be more motivated to
continue. However, clinician-initiated therapy was shown to
have very little population-level impact on the incidence of HIV.
The impact of patient-initiated therapy was higher, but still low
unless symptom recognition and treatment seeking was very
high. Although studies have shown that individuals can be
taught to recognise ulcers,
48 this would be challenging to achieve
on a large scale. The addition of acyclovir to syndromic
management guidelines for countries with a high HSV-2
prevalence
49 is only likely to have a population-level impact on
HSV-2 and HIV if symptom recognition, treatment-seeking
behaviour and correct syndromic management by providers can
be substantially improved.
Figure 2 Impact of herpes simplex virus 2 (HSV-2) therapy on the incidence of HSV-2 over 5 and 20 years in adults aged 15–49 years. For each
combination of therapy type, target group, treatment duration and coverage, three scenarios are shown corresponding to the ‘‘low’’ (H), ‘‘medium’’ (X)
and ‘‘high’’ (i) parameter sets. See Methods for full details. FSW, female sex workers; Clin init, clinician initiated; Pat init, patient initiated.
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generalised HIV epidemic in Kisumu, suppressive therapy in FSW
alonehadalmostnoeffect.Therewasaneffectintheconcentrated
HIV epidemic in Cotonou, possibly because the proportion of HIV
infections due to FSW and the population attributable fraction of
HSV-2 on the incidence of HIV among FSW is higher in
concentrated HIV epidemics. Additional treatment of clients
increased the impact in both cities, suggesting that targeting core
groupswithhigh-riskbehaviour,suchasclientsofFSW,canstillbe
an effective strategy even in some generalised HIV epidemics, but
only with high coverage and long duration. It is important to note
that the impact of 10 years of suppressive therapy was almost as
large as lifelong treatment. This suggests that HSV-2 treatment
duringthefirstfewyearsfollowinginfectionmayavertmostofthe
HIV infections preventable by HSV-2 therapy.
The general population scenarios show what could theoreti-
cally be achieved and underline the importance of HSV-2 in HIV
transmission, but long-term treatment of large proportions of
the population is unlikely to be feasible.
The impact of HSV-2 therapy on the incidence and
prevalence of HIV in the model is directly dependent on the
assumed strength of the relationship between HSV-2 and HIV.
The effects of treatment were dependent on assumptions about
the level of the co-factor effect and the relative importance of
co-factors between ulcers. Suppressive therapy might also
reduce any between-ulcer co-factor effect, although this was
not modelled, so the reductions in the effects of therapy in these
alternative scenarios may have been overestimated.
Specific assumptions about the action and mechanism of the
interventions on HSV-2 were informed by the literature
wherever possible but, as many of these interventions are not
yet well quantified or are hypothetical, a plausible range of
values was explored for uncertain parameters. Even with these
ranges, it is possible that our assumptions may have been over-
optimistic in terms of some parameters such as the high
parameter value for symptom recognition for episodic therapy.
We assumed the same symptom recognition rate for both sexes,
although it tends to be higher among men than women.
50 We
may therefore have underestimated the impact of episodic
therapy in men and overestimated it in women. However, these
effects will tend to cancel out in the results we presented on
both sexes for episodic therapy.
We have presented the hypothetical reductions in HIV
incidence and prevalence that could be achieved through HSV-
2 interventions in certain scenarios. The real-world impact of
scaled-up HSV-2 interventions would be tempered by logistical
delivery constraints, such as the feasibility of funding and
carrying out large-scale interventions in the general public, or of
locating clients of FSW and persuading them of the utility of
daily suppressive therapy for HSV-2, and by interactions with
other HIV prevention and treatment programmes. Both episodic
and suppressive therapies have limited potential as realistic HIV
interventions. To achieve the high coverage and long duration
effects on HSV-2 that are required to have an important impact
on the incidence of HIV, an effective vaccine against HSV-2 is
needed.
Figure 3 Impact of herpes simplex virus 2 (HSV-2) therapy on the incidence of HIV over 5 and 20 years in adults aged 15–49 years. For each
combination of therapy type, target group, treatment duration and coverage, three scenarios are shown corresponding to the ‘‘low’’ (H), ‘‘medium’’ (X)
and ‘‘high’’ (i) parameter sets. See Methods for full details. FSW, female sex workers; Clin init, clinician initiated; Pat init, patient initiated.
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Key messages
c Herpes simplex virus type-2 (HSV-2) infection increases
acquisition and transmission of HIV. Results from trials of HSV-
2 therapy on HIV acquisition have been disappointing, perhaps
because of insufficient herpes suppression. The potential
impact of HSV-2 therapy on the incidence of HIV at the
population level in sub-Saharan Africa is unknown.
c Simulated clinician-initiated episodic therapy in the general
population had almost no effect on the incidence of HIV. The
impact of patient-initiated therapy was higher because of
earlier treatment initiation, but still low unless symptom
recognition and treatment-seeking behaviour were very high.
c Simulated suppressive therapy in high-risk groups with high
coverage and long duration in settings with concentrated
epidemics reduced population HIV incidence in the long term.
Long-term suppressive therapy with high coverage in the
general population could substantially reduce the incidence of
HIV.
c HSV-2 therapy could potentially have a population-level impact
on HIV incidence, especially in more concentrated HIV
epidemics. However, substantial impact requires high
coverage and long duration therapy, or very high symptom
recognition and treatment-seeking behaviour. To achieve the
high coverage and long duration effects on HSV-2 that are
required to have an important impact on the incidence of HIV,
an effective vaccine against HSV-2 is needed.
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